AU2015309112A1 - Neprilysin as heart failure prognostic marker - Google Patents
Neprilysin as heart failure prognostic marker Download PDFInfo
- Publication number
- AU2015309112A1 AU2015309112A1 AU2015309112A AU2015309112A AU2015309112A1 AU 2015309112 A1 AU2015309112 A1 AU 2015309112A1 AU 2015309112 A AU2015309112 A AU 2015309112A AU 2015309112 A AU2015309112 A AU 2015309112A AU 2015309112 A1 AU2015309112 A1 AU 2015309112A1
- Authority
- AU
- Australia
- Prior art keywords
- nep
- soluble
- vitro method
- heart failure
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003729 Neprilysin Human genes 0.000 title claims abstract description 97
- 108090000028 Neprilysin Proteins 0.000 title claims abstract description 97
- 206010019280 Heart failures Diseases 0.000 title claims abstract description 86
- 239000003550 marker Substances 0.000 title claims description 6
- 238000000034 method Methods 0.000 claims abstract description 41
- 238000004393 prognosis Methods 0.000 claims abstract description 18
- 238000000338 in vitro Methods 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 238000012360 testing method Methods 0.000 claims abstract description 11
- 238000003018 immunoassay Methods 0.000 claims description 24
- 238000003556 assay Methods 0.000 claims description 22
- 210000002966 serum Anatomy 0.000 claims description 13
- 230000001684 chronic effect Effects 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 4
- 210000002381 plasma Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 27
- 230000034994 death Effects 0.000 description 23
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 13
- 239000002131 composite material Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 102400001263 NT-proBNP Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 108020001621 Natriuretic Peptide Proteins 0.000 description 6
- 102000004571 Natriuretic peptide Human genes 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 239000000692 natriuretic peptide Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 206010060933 Adverse event Diseases 0.000 description 5
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 5
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000008649 adaptation response Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- BUADUHVXMFJVLH-UHFFFAOYSA-N 7-chloro-3-imidazol-1-yl-2H-1,2,4-benzotriazin-1-ium 1-oxide Chemical compound N1[N+](=O)C2=CC(Cl)=CC=C2N=C1N1C=CN=C1 BUADUHVXMFJVLH-UHFFFAOYSA-N 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000320892 Clerodendrum phlomidis Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019283 Heart failure signs and symptoms Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101001123834 Homo sapiens Neprilysin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101800001904 NT-proBNP Proteins 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 230000002763 arrhythmic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009004 neurohormonal pathway Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000019270 symptomatic heart failure Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96497—Enkephalinase (3.4.24.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182846.7A EP2990800A1 (en) | 2014-08-29 | 2014-08-29 | Neprilysin as heartfailure (HF) prognostic marker |
| EP14182846.7 | 2014-08-29 | ||
| PCT/EP2015/068729 WO2016030209A1 (en) | 2014-08-29 | 2015-08-14 | Neprilysin as heart failure prognostic marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2015309112A1 true AU2015309112A1 (en) | 2017-04-06 |
Family
ID=51421966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015309112A Abandoned AU2015309112A1 (en) | 2014-08-29 | 2015-08-14 | Neprilysin as heart failure prognostic marker |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10203341B2 (enExample) |
| EP (2) | EP2990800A1 (enExample) |
| JP (1) | JP6661216B2 (enExample) |
| CN (1) | CN107076758B (enExample) |
| AU (1) | AU2015309112A1 (enExample) |
| CA (1) | CA2959094A1 (enExample) |
| ES (1) | ES2734876T3 (enExample) |
| MX (1) | MX2017002453A (enExample) |
| RU (1) | RU2017109086A (enExample) |
| SG (1) | SG11201701393YA (enExample) |
| WO (1) | WO2016030209A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7510649B2 (ja) | 2019-11-06 | 2024-07-04 | 国立大学法人 香川大学 | 心不全マーカー |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002322192B2 (en) * | 2001-09-03 | 2008-05-01 | Biosceptre International Limited | Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions |
| EA201290192A1 (ru) * | 2009-11-07 | 2013-02-28 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
| EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
| EP2671083A1 (en) * | 2011-02-03 | 2013-12-11 | Abbott Laboratories | Methods of prognosis and diagnosis in chronic heart failure |
| CN104303061B (zh) * | 2012-04-12 | 2017-05-31 | B.R.A.H.M.S有限公司 | 患有疑似慢性心力衰竭的患者中不良事件的预后 |
| EP3943084A1 (en) * | 2012-08-24 | 2022-01-26 | Novartis AG | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| US20140206632A1 (en) | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
| SG11201506018PA (en) * | 2013-02-14 | 2015-08-28 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| KR20150119107A (ko) * | 2013-02-14 | 2015-10-23 | 노파르티스 아게 | 개선된 생체내 효능을 갖는 nep 억제제로서의 치환된 비스페닐 부탄산 유도체 |
-
2014
- 2014-08-29 EP EP14182846.7A patent/EP2990800A1/en not_active Withdrawn
-
2015
- 2015-08-14 JP JP2017511945A patent/JP6661216B2/ja not_active Expired - Fee Related
- 2015-08-14 SG SG11201701393YA patent/SG11201701393YA/en unknown
- 2015-08-14 RU RU2017109086A patent/RU2017109086A/ru not_active Application Discontinuation
- 2015-08-14 CA CA2959094A patent/CA2959094A1/en not_active Abandoned
- 2015-08-14 EP EP15750737.7A patent/EP3186639B1/en not_active Not-in-force
- 2015-08-14 MX MX2017002453A patent/MX2017002453A/es unknown
- 2015-08-14 WO PCT/EP2015/068729 patent/WO2016030209A1/en not_active Ceased
- 2015-08-14 AU AU2015309112A patent/AU2015309112A1/en not_active Abandoned
- 2015-08-14 ES ES15750737T patent/ES2734876T3/es active Active
- 2015-08-14 CN CN201580050585.0A patent/CN107076758B/zh not_active Expired - Fee Related
- 2015-08-14 US US15/506,665 patent/US10203341B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN107076758B (zh) | 2019-10-22 |
| ES2734876T3 (es) | 2019-12-12 |
| RU2017109086A (ru) | 2018-10-01 |
| US10203341B2 (en) | 2019-02-12 |
| CN107076758A (zh) | 2017-08-18 |
| WO2016030209A1 (en) | 2016-03-03 |
| EP2990800A1 (en) | 2016-03-02 |
| EP3186639B1 (en) | 2019-03-20 |
| CA2959094A1 (en) | 2016-03-03 |
| US20170254815A1 (en) | 2017-09-07 |
| JP6661216B2 (ja) | 2020-03-11 |
| MX2017002453A (es) | 2017-10-23 |
| JP2017526924A (ja) | 2017-09-14 |
| RU2017109086A3 (enExample) | 2019-03-06 |
| SG11201701393YA (en) | 2017-03-30 |
| EP3186639A1 (en) | 2017-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120219943A1 (en) | Methods of prognosis and diagnosis in chronic heart failure | |
| KR101996123B1 (ko) | 특정 시기 내에 임신중독증의 개시를 배제하기 위한 sFlt-1/PlGF 또는 엔도글린/PlGF 비의 적용 수단 및 방법 | |
| CN109564225B (zh) | 作为指示不良事件的标志物的组蛋白和/或proADM | |
| US11307209B2 (en) | Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2 | |
| JP5945063B2 (ja) | 慢性心不全が疑われる患者における有害事象の予後 | |
| CN102203621A (zh) | 用于初次慢性肾脏疾病的发展的预后生物标志物 | |
| RU2733471C2 (ru) | Способ прогнозирования риска развития хронического заболевания почек | |
| Motiwala et al. | Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure | |
| KR20170072215A (ko) | 생물마커 및 예측 방법 | |
| Leite et al. | High sensitivity troponins: a potential biomarkers of cardiovascular risk for primary prevention | |
| JP2019525184A (ja) | 臓器障害を示すマーカーとしてのヒストンおよび／またはｐｒｏＡＤＭ | |
| US10203341B2 (en) | Neprilysin as heart failure prognostic marker | |
| Chang et al. | Utility of the serum free light chain assay in the diagnosis of light chain amyloidosis in patients with heart failure | |
| EP3311164B1 (en) | Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain | |
| US20180156822A1 (en) | Biomarker for cardiac disorders | |
| CN111065922A (zh) | 肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标 | |
| KR20190019919A (ko) | 일반 집단에서 lvh 로의 진행자 확인을 위한 가용성 st2 | |
| Anunciación-Llunell et al. | The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification | |
| Sodi | ANALYTICAL ASPECTS | |
| US20190250172A1 (en) | Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |